H13 - histocompatibility 13 Gene

Also Known as Spp; H-13; Hm13; PSL3; 1200006O09Rik; 4930443L17Rik; 5031424B04Rik

Species: Mus musculus

Gene Type: protein coding
Gene ID: 14950

Summary

Predicted to enable aspartic endopeptidase activity, intramembrane cleaving; protein homodimerization activity; and ubiquitin protein Ligase binding activity. Acts upstream of or within in utero embryonic development. Located in cell surface and endoplasmic reticulum membrane. Is expressed in several structures, including brain; embryo ectoderm; extraembryonic component; hemolymphoid system; and intervertebral disc. Orthologous to human HM13 (histocompatibility minor 13). [provided by Alliance of Genome Resources, Apr 2022]

H13 Products (4)

mRNA Protein Name
NM_001159551.2 NP_001153023.1 minor histocompatibility antigen H13 isoform 1
NM_001159552.2 NP_001153024.1 minor histocompatibility antigen H13 isoform 3
NM_001159553.2 NP_001153025.1 minor histocompatibility antigen H13 isoform 4
NM_010376.5 NP_034506.1 minor histocompatibility antigen H13 isoform 2

Gene Ontology

  • Biological Process
  • Cellular Component
Biological Process GO Annotation Evidence References Source
acts upstream of or within in utero embryonic development IMP
IMP: Inferred from mutant phenotype
27996060 MGI
Cellular Component GO Annotation Evidence References Source
located in cell surface IDA
IDA: Inferred from direct assay
16730383 MGI
located in endoplasmic reticulum IDA
IDA: Inferred from direct assay
12972007 MGI
located in endoplasmic reticulum membrane IDA
IDA: Inferred from direct assay
12972007 MGI
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

minor histocompatibility antigen H13

  • presenilin-like aspartyl protease

  • presenilin-like protein 3

  • signal peptide peptidase beta

Related Agents

  • Clinical Phase
  • Pre-clinical Phase

Clinical Phase

Bioactive Molecules (1)
Cat. No. Product Name Effect
Purity Phase
HY-19120 KB-5492 anhydrous Inhibitor 99.50% Phase 2

Pre-clinical Phase

Bioactive Molecules (13)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-B1047 Carsalam 99.91% Unkown
HY-47228 KB-5492 free base Inhibitor 99.02% Unkown
HY-137566 Cucumarioside H / Unkown
HY-162602 EGFR-IN-115 Inhibitor / Unkown
HY-RS05948 H1-3 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS06222 HM13 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS15988 ZC3H13 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-W086270 2-(4-Nitrophenyl)-1H-1,3-benzodiazole-6-carboxylic acid / Unkown
HY-W243980 2-(1H-Benzo[d]imidazol-1-yl)benzoic acid / Unkown
HY-170685 1-(2H-1,3-benzodioxol-5-yl)-2-[(propan-2-yl)amino]propan-1-one hydrochloride / Unkown
HY-170768 Alkaline tryptase-IN-1 Inhibitor / Unkown
HY-RS20618 Zc3h13 Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS27126 Zc3h13 Rat Pre-designed siRNA Set A Pre-designed Set / Unkown